Understand the source comparison
FOX04-DRI vs. Similar Peptides: Side Effect Comparison
Comparing FOX04-DRI side effects to related compounds proves challenging due to limited human data. However, other research peptides targeting cellular senescence provide some contextual framework. Epitalon, another anti-aging research peptide, demonstrates a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Comparing FOX04-DRI side effects to related compounds proves challenging due to limited human data. However, other research peptides targeting cellular senescence provide some contextual framework. Epitalon, another anti-aging research peptide, demonstrates a more established safety profile with documented human use showing minimal side effects in doses up to 10 mg daily.[5]
- FOX04-DRI
- FOXO4-p53 disruption
- Injection site reaction (15-20%)
- Unknown
- Research-only status
- Epitalon
- Telomerase activation
- Mild fatigue (5-10%)
- <5%
- <1%
- Some human data available
- GHK-Cu
- Copper peptide complex
- Skin irritation (10-15%)
- Topical application option
- Thymosin Alpha-1
- Immune modulation
- Injection site pain (20-25%)
- 1-2%
- FDA orphan drug status
- The comparison reveals FOX04-DRI's unique position as having the least characterized safety profile among senescence-targeting peptides. While GHK-Cu offers topical administration options that avoid injection site reactions, FOX04-DRI's mechanism requires systemic delivery. Thymosin Alpha-1 shows similar injection site reaction rates but benefits from extensive clinical trial data spanning decades.
- Most concerning is FOX04-DRI's potential for interfering with fundamental cellular processes compared to other anti-aging peptides that work through more targeted mechanisms. This theoretical risk profile distinguishes it significantly from compounds like epitalon, which primarily affects telomerase activity without disrupting DNA damage response pathways.[4]